Ann: Quarterly Business Review & Appendix 4C, page-2

Another disappointing quarterly. $116k sales is not what the company was portraying.

They are so good at spruiking.
At least they are consistent.

This was the market update on 27th April :

Covid-19 Environment drives demand for Oventus devices

Key highlights:
• Interest in Oventus oral devices is being driven by concern regarding CPAP’s potential
role in spreading COVID-19 virus through aerosol droplets
• Four contracted sites now scheduled to launch remotely during April, taking total
number of sites launched to 18
• Contracts signed in Canada for two new clinical sites, taking total contracted sites under
Oventus’ Lab in Lab model to 45
• Telehealth extension to Lab in Lab business model operating efficiently; building
pipeline of patient bookings
• Patient bookings since mid-March, when the gravity of the COVID-19 pandemic started
to crystallise for the US and Canada, have now exceeded total February patient bookings

Then the next day a large cap raising.

I am holding my tongue.